ZIOPHARM Oncology (ZIOP) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a buy rating to a hold rating in a research note published on Saturday morning, Zacks.com reports.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

Several other equities analysts also recently issued reports on the company. HC Wainwright reissued a buy rating and issued a $5.50 target price on shares of ZIOPHARM Oncology in a research report on Thursday, May 9th. Lake Street Capital assumed coverage on ZIOPHARM Oncology in a research report on Thursday, April 4th. They issued a buy rating and a $7.00 target price on the stock. Laidlaw assumed coverage on ZIOPHARM Oncology in a research report on Monday, April 1st. They issued a buy rating and a $7.50 target price on the stock. Finally, BidaskClub raised ZIOPHARM Oncology from a buy rating to a strong-buy rating in a research report on Wednesday, March 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $5.75.

Shares of ZIOP traded down $0.13 during midday trading on Friday, hitting $4.39. 886,686 shares of the company’s stock traded hands, compared to its average volume of 1,274,357. ZIOPHARM Oncology has a 1 year low of $1.56 and a 1 year high of $5.00. The company has a current ratio of 8.89, a quick ratio of 8.89 and a debt-to-equity ratio of 0.01.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. As a group, analysts forecast that ZIOPHARM Oncology will post -0.3 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James & Associates grew its position in ZIOPHARM Oncology by 7.2% during the 1st quarter. Raymond James & Associates now owns 60,322 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 4,061 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in ZIOPHARM Oncology by 12.3% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 52,871 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 5,802 shares during the period. Legal & General Group Plc grew its position in ZIOPHARM Oncology by 30.6% during the 4th quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 6,054 shares during the period. SG Americas Securities LLC grew its position in ZIOPHARM Oncology by 30.8% during the 1st quarter. SG Americas Securities LLC now owns 31,906 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 7,506 shares during the period. Finally, Northern Trust Corp grew its position in ZIOPHARM Oncology by 0.5% during the 4th quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock worth $3,081,000 after purchasing an additional 8,068 shares during the period. 35.20% of the stock is currently owned by institutional investors.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Recommended Story: Resistance Level

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.